Please assess the completion status of the following clinical trial:

Trial Title: The p53 Colorectal Cancer Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic colorectal cancer patients for whom conventional therapy has failed; defined as 2 lines of chemotherapy including oxaliplatin or irinotecan- containing regimens as well as an EGFR inhibitor if applicable.~* Tumor lesion suitable for biopsy~* Age \>18 years~* Clinically or radiologically measurable tumor deposits according to the RECIST criteria~* WHO performance status 0-1~* Radiology studies (CT thorax/abdomen/pelvis) and echo cor and ECG must be performed within 28 days prior to registration.~* Before patient registration in the trial, written informed consent must be given according to national and local regulations.~* Blood test requirements:~Neutrophils \> 1.0 e9/L Platelets \> 75 e9/L Bilirubin \< 20 µmol / L. Serum creatinine \< 1.5 x ULN~Exclusion Criteria:~* Co-morbidity including, but not limited to, impaired renal-, liver or bone marrow function, that based on the assessment of the treating physician, may preclude the use of cyclophosphamide at actual doses.~* Known hypersensitivity to the study drug, its metabolites or any excipients in the infusion solution.~* Psychological, familial, sociological or geographical condition(s) potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial~* Pregnant or lactating patients cannot be included.~* Clinical evidence of serious coagulopathy. Prior arterial/venous thrombosis or embolism does not exclude patients from inclusion, unless patient is considered unfit by study oncologist.~* Patient not able to give an informed consent or comply with study regulations as deemed by study investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide arm (Type: EXPERIMENTAL): Dose dense cyclophosphamide (1800 Mg/m2) administered intravenously every second week.

Based on this trial design, predict the completion outcome and termination type (if applicable).